Orthofix Med Inc SEC Filings

Orthofix Medical Inc. (Nasdaq: OFIX) filed an 8-K on 5 Aug 2025 to furnish, rather than file, its second-quarter 2025 earnings press release (Ex. 99.1) and an investor-relations slide deck (Ex. 99.2). The core 8-K text contains no quantitative results; all GAAP and non-GAAP figures must be obtained from the attached exhibits.

The company reiterates its extensive suite of non-GAAP metrics—constant-currency sales, free cash flow, adjusted gross profit/margin, adjusted operating & non-operating expenses, EBITDA and adjusted EBITDA—and enumerates the permitted adjustments such as share-based compensation, SeaSpine merger costs, litigation, succession charges and M6 product-line restructuring. Management argues these measures enhance period-over-period comparability, yet acknowledges their analytical limitations and provides GAAP reconciliations in the exhibits.

No guidance, outlook or numerical performance data appear in the filing itself; therefore the market impact will depend on figures contained in Exhibit 99.1.

Michael Finegan, Director at Orthofix Medical, reported acquiring 26,087 deferred stock units (DSUs) on June 18, 2025. The DSUs were granted at $0 and will fully vest on the first anniversary of the grant date, contingent on Finegan's continued service.

Following this transaction, Finegan beneficially owns a total of 57,391 securities, which includes:

• 26,087 newly granted DSUs
• 29,718 previously reported DSUs
• 1,586 shares acquired through Orthofix's Stock Purchase Plan on April 30, 2025

The DSUs represent a contingent right to receive one share of common stock each, with settlement occurring within 45 days of Finegan's termination of service with Orthofix. This Form 4 filing was submitted by attorney-in-fact J. Andres Cedron on June 23, 2025.

Orthofix Medical Inc. (OFIX) – Form 4 Insider Activity

Director Michael E. Paolucci filed a Form 4 reporting the grant of 18,841 deferred stock units (DSUs) on 06/18/2025. The transaction is coded “A,” indicating an acquisition from the issuer at $0 cost as part of equity compensation. Each DSU converts into one share of common stock and vests 100 % on the first anniversary of the grant, subject to continued board service. Vested units will be settled in common shares within 45 days after the director’s service ends.

After the award, Paolucci’s total reported beneficial ownership is 86,948 OFIX shares, which now comprises:

• 54,700 previously reported DSUs
• 1,341 shares purchased through the company’s Stock Purchase Plan on 10/31/2024
• The newly granted 18,841 DSUs

The filing shows no dispositions or sales and does not involve derivative securities other than the DSUs described. No exercise price, expiration, or cash outflow is associated with the grant. The form was signed by attorney-in-fact Geoffrey Gillespie on 06/23/2025.

Because the transaction is a routine equity award to a non-employee director, it does not directly alter Orthofix’s financial position. However, it modestly increases insider ownership, which some investors view as an indicator of alignment between the board and shareholders.

Orthofix Medical (NASDAQ:OFIX) filed a Form 4 disclosing that director Vickie L. Capps was granted 18,841 deferred stock units on 18 June 2025. These units vest in full one year after the grant date, contingent upon continued board service, and will convert into common shares within 45 days of her separation from the company. Following the award, Capps’ reported beneficial ownership increased to 21,934 shares, which includes 3,093 previously disclosed units. The award carries no purchase price and no insider sales were reported.

Orthofix Medical (NASDAQ: OFIX) filed a routine Form 4 disclosing that director Wayne Burris was granted 18,841 deferred stock units (DSUs) on 06/18/2025 at no cost as part of board compensation. The award vests in full one year after the grant date, provided continued service, and will convert to common stock within 45 days after the director leaves the board.

Following the grant, Burris’ total beneficial ownership increased to 50,539 shares, which includes 25,315 previously reported DSUs. The filing reports no share sales, cash proceeds, or changes to Orthofix’s operations or financial outlook.

Orthofix Medical (NASDAQ:OFIX) submitted a routine Form 4 disclosing that director Alan Lee Bazaar received 18,841 deferred stock units on 06/18/2025 as part of standard board compensation.

The units vest in full on the first anniversary of the grant date, contingent upon continued service, and convert into common stock within 45 days of the director’s termination of service. The transaction price is recorded as $0, indicating a non-cash equity award. After the grant, Bazaar beneficially owns 49,824 shares, which include 24,088 previously reported deferred stock units. No shares were sold or disposed of, and the filing notes no other material changes.

Orthofix Medical (OFIX) filed a Form 4 disclosing that director Charles R. Kummeth was granted 18,841 deferred stock units (DSUs) on 06/18/2025 at no cost. The DSUs vest in full on the first anniversary of the grant date and will convert into common stock within 45 days after his service with the company ends. Following the award, Kummeth’s total beneficial ownership rose to 59,237 shares, which now includes 23,502 previously reported DSUs and 1,894 shares accumulated through Orthofix’s Stock Purchase Plan.